.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

INSPRA Drug Profile

« Back to Dashboard
Inspra is a drug marketed by Gd Searle Llc and is included in one NDA. It is available from four suppliers. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-three patent family members in twenty-nine countries.

The generic ingredient in INSPRA is eplerenone. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the eplerenone profile page.

Summary for Tradename: INSPRA

Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Drug Prices: :see details

Pharmacology for Tradename: INSPRA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-001Sep 27, 2002RXNo6,410,054*PED► subscribeY► subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-003Sep 27, 2002DISCNNo6,534,093*PED► subscribeY► subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-001Sep 27, 2002RXNo7,157,101*PED► subscribeY► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INSPRA

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-002Sep 27, 20024,559,332*PED► subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-001Sep 27, 20024,559,332*PED► subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-003Sep 27, 20024,559,332*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: INSPRA

Drugname Dosage Strength RLD Submissiondate
eplerenoneTablets25 mg and 50 mgInspra9/27/2006

Non-Orange Book Patents for Tradename: INSPRA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,592,902 Controlled release eplerenone compositions► subscribe
6,863,902 Immediate release eplerenone compositions► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INSPRA

Country Document Number Estimated Expiration
South Africa200104361► subscribe
Australia3394500► subscribe
Portugal1165136► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INSPRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1135139/01Switzerland► subscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
04C/008Belgium► subscribePRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc